KIMIA FARMA -B-
PT Kimia Farma (Persero) Tbk produces and sells medicines, herbal medicines, iodine, salts, quinine and their derivative products, and vegetable oils in Indonesia, rest of Asia, Europe, Australia, Africa, and New Zealand. The company operates through Manufacturing, Distribution, Retail, and Other Services segments. It also manufactures and markets chemical, betalactam and non betalactam, antiretr… Read more
KIMIA FARMA -B- (HQP) - Total Assets
Latest total assets as of June 2025: €14.97 Trillion EUR
Based on the latest financial reports, KIMIA FARMA -B- (HQP) holds total assets worth €14.97 Trillion EUR as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
KIMIA FARMA -B- - Total Assets Trend (2016–2024)
This chart illustrates how KIMIA FARMA -B-’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
KIMIA FARMA -B- - Asset Composition Analysis
Current Asset Composition (December 2024)
KIMIA FARMA -B-'s total assets of €14.97 Trillion consist of 26.3% current assets and 73.7% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 2.9% |
| Accounts Receivable | €1.17 Trillion | 7.8% |
| Inventory | €1.50 Trillion | 10.1% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €57.03 Billion | 0.4% |
| Goodwill | €53.68 Billion | 0.4% |
Asset Composition Trend (2016–2024)
This chart illustrates how KIMIA FARMA -B-'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: KIMIA FARMA -B-'s current assets represent 26.3% of total assets in 2024, a decrease from 63.0% in 2016.
- Cash Position: Cash and equivalents constituted 2.9% of total assets in 2024, down from 14.0% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2016.
- Asset Diversification: The largest asset category is inventory at 10.1% of total assets.
KIMIA FARMA -B- Competitors by Total Assets
Key competitors of KIMIA FARMA -B- based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
C.Q. Pharmaceutical Holding Co Ltd
SHE:000950
|
China | CN¥67.71 Billion |
|
Shenzhen Glory Medical Co Ltd
SHE:002551
|
China | CN¥3.56 Billion |
|
Shandong Realcan Pharmaceutical Co Ltd
SHE:002589
|
China | CN¥15.33 Billion |
|
Hanmi Science
KO:008930
|
Korea | ₩1.45 Trillion |
|
BCM Alliance Bhd
KLSE:0187
|
Malaysia | RM147.86 Million |
|
Qingdao Baheal Medical INC.
SHE:301015
|
China | CN¥7.59 Billion |
|
Excelsior Medical Co Ltd
TW:4104
|
Taiwan | NT$18.80 Billion |
|
CHC Healthcare Group
TW:4164
|
Taiwan | NT$14.83 Billion |
KIMIA FARMA -B- - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - KIMIA FARMA -B- generates 0.66x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - KIMIA FARMA -B- is currently not profitable relative to its asset base.
KIMIA FARMA -B- - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.59 | 0.61 | 0.89 |
| Quick Ratio | 0.39 | 0.37 | 0.46 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €-2.80 Trillion | € -3.52 Trillion | € -810.75 Billion |
KIMIA FARMA -B- - Advanced Valuation Insights
This section examines the relationship between KIMIA FARMA -B-'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.70 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -10.0% |
| Total Assets | €14.97 Trillion |
| Market Capitalization | $78.59 Million USD |
Valuation Analysis
Below Book Valuation: The market values KIMIA FARMA -B-'s assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: KIMIA FARMA -B-'s assets decreased by 10.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for KIMIA FARMA -B- (2016–2024)
The table below shows the annual total assets of KIMIA FARMA -B- from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €14.97 Trillion | -10.00% |
| 2023-12-31 | €16.63 Trillion | -16.00% |
| 2022-12-31 | €19.80 Trillion | +14.91% |
| 2021-12-31 | €17.23 Trillion | -1.90% |
| 2020-12-31 | €17.56 Trillion | -4.30% |
| 2019-12-31 | €18.35 Trillion | +94.00% |
| 2018-12-31 | €9.46 Trillion | +55.19% |
| 2017-12-31 | €6.10 Trillion | +32.16% |
| 2016-12-31 | €4.61 Trillion | -- |